Data collaboration platform Datavant has partnered with life sciences commercialisation company Indegene to enhance recruitment of subjects for clinical studies.
This partnership places particular emphasis on studies concerning rare diseases and other complex conditions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
By leveraging Datavant’s data enrichment offerings and Indegene’s NEXT Patient Recruitment platform, the collaboration allows biopharma companies to reduce screen failures at the site level.
The partnership also enables quicker enrolment times, screen-to-randomisation ratios, and decision-making in the recruitment process.
Datavant Life Sciences GM and president Arnaub Chatterjee said: “Rare diseases have long been defined by the impossibility of finding enough patients fast enough to bring new therapies to market.
“Together with Indegene, we are demonstrating how data enrichment solves that challenge today – and lays the foundation for a new model of clinical research in which sponsors can accelerate recruitment across even the most complex and hard-to-reach populations.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDatavant noted that its health data retrieval network includes data from more than 80,000 hospitals and clinics, and processes in excess of 100 million records of patients each year.
This extensive reach, paired with Indegene’s digitally powered solutions for trial recruitment, is intended to facilitate the detection of potential subjects who meet certain health data criteria for various trials.
The anticipated outcome of this partnership is an improved connection between eligible subjects and trials that are relevant to their specific health conditions.
Indegene enterprise clinical solutions senior vice-president Ram Yeleswarapu said: “We are doubling down on enhancing our capabilities to deliver digital-first recruitment solutions for clients to transform clinical trial execution.
“By integrating secure, real-time access to consented patient medical records into our screening process, we are minimising one of the greatest challenges in clinical trials – screen failures at sites due to incomplete and ineffective pre-screening.
“This collaboration reinforces our positioning as the industry’s premier digital-first recruitment partner, empowering sponsors and sites with data-driven approaches that deliver measurable outcomes.”
